Why Is NeuroPace Stock Falling After Epilepsy Treatment Study Data?

NeuroPace's NAUTILUS study for drug-resistant idiopathic generalized epilepsy (IGE) met its primary safety endpoint but did not achieve statistical significance for the primary effectiveness endpoint in the overall study population; however, a subgroup with lower baseline seizure frequency showed statistically significant benefit. Despite this, the company reported clinically relevant data across the entire trial population, including improvements in median percent seizure reduction and responder rates over the first year. NeuroPace is engaging with the FDA to discuss regulatory pathways, potentially focusing on patients with lower baseline seizure frequency, and raised its fiscal year 2025 sales guidance to $93 million-$97 million; NPCE stock is down 33.90%.

Analysis

NeuroPace, Inc. (NPCE) announced mixed preliminary one-year results from its NAUTILUS study evaluating the RNS System for drug-resistant idiopathic generalized epilepsy (IGE). The study successfully met its primary 12-week post-implant safety endpoint, indicating a low rate of serious adverse events. However, it did not achieve statistical significance for its primary effectiveness endpoint in the overall study population, which aimed to show a longer time to a second generalized tonic-clonic seizure in the active stimulation group versus the sham group. Notably, a subgroup of patients with lower baseline seizure frequency, constituting most trial participants, did show a statistically significant benefit on this primary effectiveness endpoint. Furthermore, NeuroPace reported that the entire trial population demonstrated numerically robust and clinically meaningful improvements in median percent seizure reduction, responder rates, and seizure-free days over the first year, with these trends continuing into the second year. The company intends to engage with the FDA to discuss regulatory pathways, potentially focusing on the overall median seizure reduction data or a more targeted indication for patients with lower baseline seizure frequency. Despite these clinical developments, NeuroPace reported strong financial performance, with first-quarter 2025 sales growing 24% to $22.5 million, and RNS System revenue increasing 29% (excluding revenue from NAUTILUS study implants in Q1 2024). This led to an upward revision of its fiscal year 2025 sales guidance to $93 million-$97 million, from a prior $92 million-$96 million, surpassing the consensus of $93.64 million. Nevertheless, NPCE stock reacted negatively to the study news, declining 33.90% to $11.68. The company also announced the termination of its SEEG product distribution relationship, effective Q4 2025 through Q1 2026, and earlier in April, reported positive three-year data from its RNS System Post-Approval Study in focal epilepsy, showing an 82% median seizure reduction.

Key Decisions for Investors

• Investors should closely monitor NeuroPace's forthcoming discussions with the FDA regarding regulatory pathways for the RNS System in IGE, as the outcome will significantly influence the product's market expansion potential and future revenue streams.
• The substantial stock price decline of 33.90% presents a valuation question; investors should weigh the risks associated with the primary endpoint miss in the NAUTILUS study's overall population against the company's robust Q1 sales growth, increased FY2025 guidance, and the statistically significant benefit observed in the IGE patient subgroup with lower seizure frequency.
• Consider the impact of the SEEG product distribution termination, scheduled for late 2025 to early 2026, on future revenue composition, while acknowledging the continued strong growth of the core RNS System.
• Recognize that the market's sharp negative reaction underscores the high sensitivity to clinical trial outcomes for NPCE, suggesting future clinical or regulatory catalysts could also result in significant stock price volatility.